Scholarlink

<p>Premature ovarian insufficiency (POI) is a complex disorder characterized by hypoestrogenism, elevated gonadotropins, and menstrual irregularity or amenorrhea. Effective treatments remain limited, but advances in reproductive biology have highlighted long noncoding RNAs (lncRNAs) as pivotal regulators of granulosa cell function and follicular development. Growing evidence shows that lncRNAs contribute to POI pathogenesis and hold promise as diagnostic biomarkers and therapeutic targets. This review summarizes recent findings on the lncRNA-mediated regulation of granulosa cell proliferation, autophagy, apoptosis, hormone signalling, mitochondrial stress, glycolysis, and DNA damage and discusses current limitations—including small sample sizes, limited in vivo validation, and translational challenges—that hinder clinical application. Although lncRNAs represent an emerging frontier in POI research, their diagnostic and therapeutic value requires further validation before clinical integration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The implications of LncRNAs and premature ovarian insufficiency

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Qian Zhao,
  • Xuan-ling Li,
  • Guang-yao Lin,
  • Chen-lin Sui,
  • Bao-fang Zhang,
  • Yu-quan Bai,
  • Lian-wei Xu

摘要

Premature ovarian insufficiency (POI) is a complex disorder characterized by hypoestrogenism, elevated gonadotropins, and menstrual irregularity or amenorrhea. Effective treatments remain limited, but advances in reproductive biology have highlighted long noncoding RNAs (lncRNAs) as pivotal regulators of granulosa cell function and follicular development. Growing evidence shows that lncRNAs contribute to POI pathogenesis and hold promise as diagnostic biomarkers and therapeutic targets. This review summarizes recent findings on the lncRNA-mediated regulation of granulosa cell proliferation, autophagy, apoptosis, hormone signalling, mitochondrial stress, glycolysis, and DNA damage and discusses current limitations—including small sample sizes, limited in vivo validation, and translational challenges—that hinder clinical application. Although lncRNAs represent an emerging frontier in POI research, their diagnostic and therapeutic value requires further validation before clinical integration.